media – Page 236 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Improve education, health equity to boost cervical cancer screening

Education needs to improve for cervical cancer screening to help drive down cases of a tumor type that kills more than 340,000 people a year. That is a takeaway from a Harris Poll survey of women in the U.S., U.K. and Sweden that identified confusion about screening as a barrier to effective preventative care. BD, which sells a test for the cancer-causing human papillomavirus (HPV), publicized the results of the survey. The poll found most women see cervical cancer screening a key part of their health management, with the percentage ranging from 76% in the U.S. to 86% in Sweden, but their grasp of the specifics can be shaky. Between 55% and 59% of women find the screening guidance confusing. In Sweden, 28% of women say they are knowledgeable about cervical cancer screening options. The figures are higher in the U.S. and U.K., 59% and 62%, respectively, but other responses ...
- Source: drugdu
- 118
- January 17, 2024
CAR-T hype faces infrastructure reality check

Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times hindered these cell-based treatments. As biopharma companies clear those hurdles, a larger, more systemic problem now threatens the drug class. Six CAR-T therapies targeting either CD19 or BCMA have reached the U.S. market to treat various blood cancers. Impressive efficacy data, wide reimbursement acceptance, earlier-line approvals and steady production expansions have fueled blockbuster revenue predictions. But drug developers and Wall Street may have underestimated the bottlenecks from the healthcare infrastructure needed to deliver a cell therapy, Leerink Partners analyst Daina Graybosch, Ph.D., warns. CAR-T therapies are indeed on a fast trajectory of growth. By 2027, when the drug class celebrates its first decennial anniversary, Johnson & Johnson expects its Legend Biotech-partnered Carvykti—the last of the six existing CAR-T products to hit the market—will have reached about ...
- Source: drugdu
- 316
- January 17, 2024
Pfizer’s eye for China ADC deals; Astellas’ gastric cancer rejection

Pfizer is still hungry for ADC opportunities, including in the Far East. Astellas’ impressive phase 3 data for its gastric cancer candidate couldn’t garner an approval because of manufacturing issues. Takeda’s 2022 TYK2 buy from Nimbus was highly competitive, an exec said. And more. 1. JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals As Pfizer continues its prowl for antibody-drug conjugate (ADCs) deals, the company is keeping an eye on opportunities around the globe. In an interview, Pfizer’s new oncology chief Chris Boshoff, Ph.D., said the company is looking for opportunities in China, which he said “is important in this whole area, especially ADC development.” The company is “not currently looking for big acquisitions,” Boshoff added. 2. Astellas’ gastric cancer candidate rejected by FDA because of manufacturing issues After running two phase 3 trials, Astellas’ near-term approval ambitions for its zolbetuximab have been dashed because of ...
- Source: drugdu
- 150
- January 17, 2024
【EXPERT Q&A】How to Start a Medical Device Trading Company?

Drugdu.com expert’s response: Medical trade, encompassing international exchanges of goods and services in the healthcare sector, is a distinct kind of commerce. Like other commodities, the trade of medical services includes both imports and exports. The essence of medical service trade lies in the local export of goods and services, characterized by its comprehensive and integrative nature. a. Local Export of Goods In countries or regions providing medical facilities, expenses incurred by international patients and their families for medical care, food, accommodation, transportation, tourism, shopping, and entertainment are paid in foreign currency. This method of generating foreign exchange revenue essentially represents a form of local export trade, realized through the provision of medical services on-site. b. Local Export of Services Apart from purchasing and consuming medical material products, patients and their families also utilize various service-related activities, as medical products inherently involve a significant proportion of service labor. For example, the ...
- Source: drugdu
- 256
- January 16, 2024
Benchtop Analyzer Promises 1-Hour UTI Detection and Antibiotic Sensitivity Indication

More than 400 million cases of urinary tract infections (UTIs) are reported every year across the world. The gold standard for diagnosing UTIs and planning a treatment course depends on rapid dipstick tests and clinical diagnostic analysis. However, dipsticks have low specificity and can yield false positives, resulting in the overuse of antibiotics. Additionally, clinical tests have a lengthy turnaround time and offer 80% accuracy, resulting in physicians opting for the wrong course of treatment. Now, a benchtop analyzer with the ability to accurately identify the causative bug and the right antibiotic in under an hour could be a game changer for UTI diagnosis. Astek Diagnostics (Baltimore, MD, USA) is developing the JIDDU benchtop analyzer to improve UTI diagnosis through rapid, one-hour turnaround times and an unprecedented 96% accuracy. Leveraging a novel method for antibiotic susceptibility testing (AST), JIDDU rapidly detects bacterial infections in urine samples, assesses infection severity, and ...
- Source: drugdu
- 171
- January 16, 2024
Hundreds of chemicals linked to breast cancer risk identified in new study

In a recent study published in the journal Environmental Health Perspectives, researchers examined published studies investigating the genotoxicity of potentially carcinogenic chemicals and their roles in inducing mammary tumors and activating progesterone or estradiol signaling. The researchers aimed to identify chemicals that could present breast cancer risk to humans. Background Recent statistics indicate that breast cancer is the most prevalent form of cancer and the major cause of cancer-related mortality among women across the world. In the United States (U.S.), the lifetime risk of women developing breast cancer is double that of the risk of developing lung cancer. Furthermore, the incidence of breast cancer among younger women is increasing, with mortality rates due to breast cancer among women between the ages of 20 and 49 years being double that of other forms of cancers affecting individuals of both sexes. A nine-year assessment since 2010 also indicates that the diagnostic rate ...
- Source: drugdu
- 233
- January 16, 2024
Dexcom Announces Preliminary and Unaudited Revenue For Fourth Quarter and Fiscal Year 2023

Mike Hollan The company also announced that it has submitted its new glucose monitoring system to the FDA for approval. Dexcom announced that the company’s revenue for the fourth quarter of 2023 is expected to be at least $1.03 billion in a presentation at the JP Morgan Healthcare Conference. These numbers are preliminary and unaudited. This revenue would be a 26% over the earnings of the same quarter in the previous year. Similarly, the preliminary and unaudited revenue for the fiscal year 2023 is expected to $3.62 billion. Dexcom is a San Diego-based company that develops, manufactures, and sells continuous glucose monitoring systems for diabetes. In a press release, Dexcom’s chairman, president, and CEO Kevin Sayer said, “Dexcom had an incredible year in 2023 with the largest expansion of coverage in our company’s history, a successful rollout of Dexcom G7 in the U.S. and expansion of G7 to more than ...
- Source: drugdu
- 159
- January 16, 2024
Manufacturing Issues Block Astellas From a First-in-Class Cancer Drug Approval

Astellas Pharma’s zolbetuximab was on track to become the first gastric cancer drug that targets claudin 18.1, a protein found on cancerous stomach cells. Others with clinical-stage programs addressing this this target include AstraZeneca and Bristol Myers Squibb. By FRANK VINLUAN Astellas Pharma’s path to winning the first drug approval for a particular promising gastrointestinal cancer target has hit a detour. The FDA turned down the drugmaker’s application, citing manufacturing issues for the therapy, zolbetuximab. Astellas announced the FDA action earlier this week. The company did not go into detail about the problems spotted by the regulator, but described them as “unresolved deficiencies following its pre-license inspection of a third-party manufacturing facility for zolbetuximab.” Astellas added that the agency did not raise any concerns about the safety or efficacy of the drug, nor is it asking for additional clinical data. Zolbetuximab was developed as a treatment for patients with locally ...
- Source: drugdu
- 256
- January 16, 2024
CAR-T drug launches pay-per-therapeutic-value program with up to 600,000 yuan drug rebate

On January 11, Fosun Kate and Chenshi Health, a health management and comprehensive patient service platform under Sinopharm Holdings, jointly launched the first lymphoma pay-per-therapeutic value plan for Ekeda in China. Eligible patients who fail to achieve complete remission (CR) after treatment with Ekeda, a CAR-T treatment that originally cost $1.2 million, will receive a rebate of up to RMB600,000. The program will be China’s first innovative payment model for lymphoma drugs paid by the value of efficacy, and Ekeda will be China’s first bioinnovative drug paid by the value of efficacy. “If the complete remission indicator is not reached at three months, even if there is efficacy but the efficacy is not as good as complete remission, half of their out-of-pocket drug purchase price will still be refunded under the program. If this patient’s medication is completely self-funded, then the maximum return is 600,000 RMB for the medication. If ...
- Source: drugdu
- 231
- January 16, 2024
Rehabilitation New Drug Fund Incubatees Featured at J.P. Morgan Healthcare Conference

The 42nd Annual J.P. Morgan Healthcare Conference (hereinafter referred to as “JPM Conference”) was held on January 8-11, 2024 in San Francisco, California, USA. The conference invited “big names” from the pharmaceutical industry and the international investment and financing community to discuss cutting-edge advances in the industry and new trends for future development. Three companies incubated by Rehabilitation Capital’s New Drug Innovation Fund, namely, StarMed Unigene, StarNucleus Disease, and StarOptoVision, attended the JPM conference and delivered speeches in the biotechnology session, which gained great response. The company deeply participated in the international exchange of global biopharmaceuticals, laying the foundation for future innovation cooperation and exploring sustainable cooperation opportunities. JPM Conference has been held for 41 years since 1983, is the largest and most informative healthcare investment seminar in the global biomedical health field, which connects nearly 10,000 industry leaders, representatives of innovative enterprises, technology developers and investors worldwide, and is ...
- Source: drugdu
- 163
- January 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.